Prognostic Factors for Advanced/Recurrent Breast Cancer Treated With Immune-cell Therapy
/in Breast Cancer, Dendritic Cells, International Publications /von 2021-08-01 / Anticancer Res 2021 Aug;41(8):4133-4141Prophylactic Dendritic Cell Vaccination in Experimental Breast Cancer Controls Immunity and Hepatic Metastases
/in Breast Cancer, Dendritic Cells, International Publications /von 2021-07-01 / Anticancer Res 2021 Jul;41(7):3419-3427CD133 mRNA-transfected dendritic cells induce coordinated cytotoxic and helper T cell responses against breast cancer stem cells
/in Breast Cancer, Dendritic Cells, International Publications /von 2021-05-19 / Mol Ther Oncolytics 2021 Sep;22:64-71Modulated Electro-Hyperthermia Induces a Prominent Local Stress Response and Growth Inhibition in Mouse Breast Cancer Isografts
/in Breast Cancer, Hyperthermia, International Publications /von 2021-04-06 / Cancers (Basel) 2021 Apr;13(7)Clinical study of modulated electro-hyperthermia for advanced metastatic breast cancer
/in Breast Cancer, Hyperthermia, International Publications /von 2021-03-17 / Mol Clin Oncol 2021 May;14(5):103Adoptive Cell Therapy in Breast Cancer: A Current Perspective of Next-Generation Medicine
/in Breast Cancer, Dendritic Cells, International Publications /von 2020-10-27 / Front Oncol 2020;10:605633Evaluation of Apoptosis Induction by Newcastle Disease Virus LaSota Strain in Human Breast Carcinoma Cells
/in Breast Cancer, International Publications, Newcastle Disease Virus /von 2020-10-01 / Arch Razi Inst 2020 10;75(3):367-376NDV-D90 inhibits 17β-estradiol-mediated resistance to apoptosis by differentially modulating classic and nonclassic estrogen receptors in breast cancer cells
/in Breast Cancer, International Publications, Newcastle Disease Virus /von 2020-09-28 / J Cell Biochem 2021 Jan;122(1):3-15Exhaustion of Protective Heat Shock Response Induces Significant Tumor Damage by Apoptosis after Modulated Electro-Hyperthermia Treatment of Triple Negative Breast Cancer Isografts in Mice
/in Breast Cancer, Hyperthermia, International Publications /von 2020-09-10 / Cancers (Basel) 2020 Sep;12(9)
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de